Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.
Aim(s): To evaluate the efficacy and toxicity of BEV-containing protocols in NEN.
Materials and methods: We performed a retrospective analysis of all NEN patients who were treated with BEV-containing protocols at our center between August 2008 and November 2017.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Dr. med. Leonidas Apostolidis
To read results and conclusion, please login ...
Further abstracts you may be interested in